Table 2.
Broad-spectrum inhibitory activity of lead compounds against a panel of human CoVs. (IC50, μM)
| Bota coronavirus | Alpha coronavirus | ||||||
|---|---|---|---|---|---|---|---|
| No | SARS-CoV-2 IC50 (μM) | SARS-CoV IC50 (μM) | MERS-CoV IC50 (μM) | HCoV-OC43 IC50 (μM) | HKU1 IC50 (μM) | HCoV-229E IC50 (μM) | HCoV-NL63 IC50 (μM) |
| M-1-3 | 0.08±0.01 | 0.16±0.01 | 0.41±0.05 | 0.71±0.02 | 0.033±0.01 | 0.062±0.01 | 0.89±0.01 |
| M-1-4 | 0.95±0.04 | 0.73±0.10 | >20 | 3.67±0.63 | 1.21±0.20 | 0.61±0.09 | 9.58±1.79 |
| M-1-6 | 0.08±0.01 | 0.25±0.02 | 0.85±0.21 | 0.18±0.01 | 0.12±0.02 | 0.18±0.02 | 0.48±0.06 |
| M-2-3 | 1.31±0.10 | 2.26±0.39 | 8.02±2.07 | 0.12±0.01 | 0.39±0.03 | 0.69±0.08 | 0.83±0.10 |
| M-2-8 | 2.14±0.09 | 3.88±0.67 | >20 | 2.60±0.45 | 2.23±0.46 | 5.67±0.49 | 10.84±2.21 |
| GC376 | 0.03±0.01 | 0.079±0.01 | 0.11±0.02 | 0.011±0.01 | 0.012±0.03 | 0.069±002 | 0.12±0.02 |